Trial · NCT00820170
Adverse events285
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 285
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Investigations | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg | 1 | 3 | |
| other | ALT, SGPT | Investigations | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg | 1 | 5 | |
| other | ALT, SGPT | Investigations | Phast 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg | 0 | 3 | |
| other | ALT, SGPT | Investigations | Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg | 6 | 40 | |
| other | ALT, SGPT | Investigations | No Arm Selected | 0 | 4 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg | 1 | 3 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg | 1 | 5 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Phast 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg | 0 | 3 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg | 1 | 40 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | No Arm Selected | 0 | 4 | |
| other | Hyperbilirubinemia | Investigations | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg | 1 | 3 | |
| other | Hyperbilirubinemia | Investigations | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg | 1 | 5 | |
| other | Hyperbilirubinemia | Investigations | Phast 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg | 0 | 3 | |
| other | Hyperbilirubinemia | Investigations | Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg | 2 | 40 | |
| other | Hyperbilirubinemia | Investigations | No Arm Selected | 0 | 4 | |
| other | Creatinine | Investigations | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 100 mg | 1 | 3 | |
| other | Creatinine | Investigations | Phase 1: Paclitaxel 80 mg/m2 + Dasatinib 150 mg | 0 | 5 | |
| other | Creatinine | Investigations | Phast 1: Paclitaxel 80 mg/m2 + Dasatinib 70 mg | 0 | 3 | |
| other | Creatinine | Investigations | Phase 2: Paclitaxel 80 mg/m2 + Dasatinib 120 mg | 0 | 40 | |
| other | Creatinine | Investigations | No Arm Selected | 0 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00820170/events